Literature DB >> 7075114

Effects of cimetidine on caffeine disposition in smokers and nonsmokers.

D C May, C H Jarboe, A B VanBakel, W M Williams.   

Abstract

The absorption, distribution, and elimination of caffeine, 2 mg/kg by mouth, were evaluated in six smokers and six nonsmokers before and on the fourth day of administration of cimetidine, 300 mg by mouth every 6 hr. Caffeine absorption, assessed by the maximal serum caffeine concentration (C max) and the time to reach Cmax (t max), was very rapid relative to elimination. The total body clearance (TBC) of caffeine was higher (2.49 +/- 0.35 and 1.59 +/- 0.19 ml/kg/min, P less than 0.05) and the elimination half-life (t1/2) shorter (190 +/- 15 and 276 +/- 30 min, P less than 0.05) in smokers than nonsmokers, but Cmax, tmax, and the apparent volume of distribution (Vd, app) did not differ (P greater than 0.05). Cimetidine decreased the TBC of caffeine by 31% (to 1.73 +/- 0.28 ml/kg/min, P less than 0.05) and by 42% (to 0.92 +/- 0.11 ml/kg/min, P less than 0.01) in smokers and nonsmokers. The increases in t1/2 were 45% (to 276 +/- 25 min, P less than 0.05) and 96% (to 542 +/- 123 min, P less than 0.05). Cmax, tmax, and Vd, app were unaffected by cimetidine. Caffeine induced similar slight increases in blood pressure and pulse rate in smokers and nonsmokers both before and during cimetidine dosing.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075114     DOI: 10.1038/clpt.1982.91

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

Review 1.  The impact of caffeine on vasodilator stress perfusion studies.

Authors:  Andre C Lapeyre; Tauqir Y Goraya; Donald L Johnston; Raymond J Gibbons
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

2.  Drug interactions through binding to cytochrome p 450: the experience with h2-receptor blocking agents.

Authors:  U Klotz; I W Reimann
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.

Authors:  Laurence Gabriel; Michel Tod; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

5.  Factors affecting the response to inhibition of drug metabolism by cimetidine--dose response and sensitivity of elderly and induced subjects.

Authors:  J Feely; L Pereira; E Guy; N Hockings
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

6.  Femoxetine and cimetidine: interaction in healthy volunteers.

Authors:  J Schmidt; A S Sørensen; A Gjerris; O J Rafaelsen; H Mengel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Effect of cimetidine on digoxin disposition in peptic ulcer patients.

Authors:  M Garty; G Perry; H Shmueli; D Ilfeld; G Boner; S Pitlik; J Rosenfeld
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Lack of interaction of ranitidine with amitriptyline.

Authors:  S H Curry; C L DeVane; M M Wolfe
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 9.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

10.  Lack of effect of cimetidine on cigarette smoking.

Authors:  R Bendayan; G Kennedy; R C Frecker; E M Sellers
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.